InsidersTradesSigma
Follow the Zynerba Pharmaceuticals, Inc. share price and the full insider trade history of the company, a listed equity based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Zynerba Pharmaceuticals, Inc. has recorded 61 reports. The latest transaction was reported on 11 October 2023 (U). Among the most active insiders: Fickenscher James E. The full history is free.
61
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€51,420
5 ops.
Sell Volume
37Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 11 October 2023
Declarations61 total
40,520 sharesCommon StockSEC:0001140361-23-047746:0
27,954 sharesCommon StockSEC:0001140361-23-047725:0
123,087 sharesCommon StockSEC:0001140361-23-047742:0
27,954 sharesCommon StockSEC:0001140361-23-047743:0
33,685 sharesCommon StockSEC:0001140361-23-047729:0
27,954 sharesCommon StockSEC:0001140361-23-047731:0
27,954 sharesCommon StockSEC:0001140361-23-047735:0
32,941 sharesCommon StockSEC:0001140361-23-047727:0
69,559 sharesCommon StockSEC:0001140361-23-047733:0
341,241 sharesCommon StockSEC:0001140361-23-047738:0
566,722 sharesCommon StockSEC:0001140361-23-047723:0
27,954 sharesCommon StockSEC:0001140361-23-047722:0
22,200 sharesCommon StockSEC:0001062993-23-018021:0
31,200 sharesCommon StockSEC:0001062993-23-018020:0
9,000 sharesCommon StockSEC:0001062993-23-018019:0
45,000 sharesCommon StockSEC:0001062993-23-018022:0
64,747 sharesCommon StockSEC:0001062993-23-018018:0
47,824 shares0Common StockSEC:0001062993-23-013668:0
47,824 shares0Common StockSEC:0001062993-23-013665:0
47,824 shares0Common StockSEC:0001062993-23-013666:0
47,824 shares0Common StockSEC:0001062993-23-013663:0
47,824 shares0Common StockSEC:0001062993-23-013664:0
47,824 shares0Common StockSEC:0001062993-23-013667:0
3,173 shares@ US$0.5418100.0% of flowCommon StockSEC:0001062993-23-004049:0
22,547 sharesCommon StockSEC:0000899243-23-004444:0
25 of 61 declarations
关于 Zynerba Pharmaceuticals, Inc.
Zynerba Pharmaceuticals, Inc.是一家美国生物制药公司,在市场参与者中以发展阶段专科制药公司著称,历来与SEC备案和内部人士交易报告相关联。该公司于2007年在特拉华州注册成立,初名为AllTranz, Inc.,后于2014年更名为Zynerba Pharmaceuticals, Inc.。公司总部位于美国,其股份在美国市场上市,具体为NASDAQ,这使该公司处于高度监管的美国公开股权和生物技术生态系统内。([sec.gov](https://www.sec.gov/Archives/edgar/data/1621443/000155837019010074/zyne-20190930x10q.htm?utm_source=openai)) 在运营方面,Zynerba一直是一家专注于临床阶段的公司,而非多元化制药平台。其核心理念围绕针对罕见和近罕见神经精神疾病的药物制造经皮给药大麻素疗法展开。公司的主要开发工作历来针对脆性X综合征(FXS)和22q11.2缺失综合征,而早期披露中也提及自闭症谱系障碍和一组罕见癫痫。在SEC披露中,Zynerba将自身描述为优先在FXS和22q11.2上配置资源,这两种疾病均无批准的产品。这使该公司成为典型的高风险、高回报生物技术故事:管线集中、存在重大未满足的医疗需求,但面临重大临床、监管和融资风险。([sec.gov](https://www.sec.gov/Archives/edgar/data/1621443/000155837023004765/zyne-20221231x10k.htm?utm_source=openai)) Zynerba定位的一个关键要素是其经皮给药方法。理论上,皮肤给药的大麻素制剂可以相比某些口服方法提供差异化的便利性、更稳定的暴露和潜在更好的耐受性。也就是说,商业护城河完全取决于疗效、安全性、可制造性和监管批准的证明,这些在孤儿神经学领域都不能保证。Zynerba还强调了FDA对FXS和22q11.2缺失综合征中大麻二酚的孤儿药认定,以及欧洲委员会孤儿药地位,以及FDA对与FXS相关行为症状的快速通道认定。这些认定在战略上可能很有价值,但不能替代成功的后期数据或最终商业化。([sec.gov](https://www.sec.gov/Archives/edgar/data/1621443/000155837023004765/zyne-20221231x10k.htm?utm_source=openai)) 从竞争角度来看,Zynerba在一个狭窄但拥挤的科学竞争中运营:罕见神经精神和神经学疾病吸引了生物技术、学术和制药竞争对手追求基因疗法、小分子和其他精准方法。Zynerba的差异化在于大麻素/经皮给药角度,但投资者关注主要由二元临床里程碑、现金跑道和资本市场事件驱动,而非收入生成。最近的SEC材料继续将该公司描述为临床阶段专科制药企业,强调其对开发成果和融资能力的依赖。对于国际投资者,特别是分析美国上市医疗保健小盘股的欧洲投资者,Zynerba体现了NASDAQ生物技术的风险概况:管线集中暴露、重度监管依赖,以及价值主张与未来数据而非当前销售相关联。([sec.gov](https://www.sec.gov/Archives/edgar/data/1621443/000110465923048382/tm2311178d2_ars.pdf?utm_source=openai))
